Your browser doesn't support javascript.
loading
Corrigendum to 'Phase Ib dose-finding study of abiraterone acetate plus buparlisib (BKM120) or dactolisib (BEZ235) in patients with castration-resistant prostate cancer' [European Journal of Cancer 76 (2017) 36-44].
Massard, Christophe; Chi, Kim Nguyen; Castellano, Daniel; de Bono, Johann; Gravis, Gwenaelle; Dirix, Luc; Machiels, Jean-Pascal; Mita, Alain; Mellado, Begoña; Turri, Sabine; Maier, Joan; Csonka, Denes; Chakravartty, Arunava; Fizazi, Karim.
Afiliação
  • Massard C; Drug Development Department, Gustave Roussy, University of Paris Sud, Villejuif, France; Department of Cancer Medicine, Gustave Roussy, University of Paris Sud, Villejuif, France. Electronic address: christophe.massard@gustaveroussy.fr.
  • Chi KN; BC Cancer Agency, Vancouver, Canada.
  • Castellano D; University Hospital 12 de Octubre, CIBER-ONC, Madrid, Spain.
  • de Bono J; Institute of Cancer Research, London, UK.
  • Gravis G; Institut Paoli-Calmettes, Marseille, France.
  • Dirix L; St. Augustinus Hospital, Antwerp, Belgium.
  • Machiels JP; Institut Roi Albert II, Service d'Oncologie Médicale, Cliniques universitaires Saint-Luc and Institut de Recherche Clinique et Expérimentale, Universitécatholique de Louvain, Brussels, Belgium.
  • Mita A; Cedars-Sinai Medical Center, Los Angeles, CA, USA.
  • Mellado B; Medical Oncology Department, Hospital Clínic, IDIBAPS, Barcelona, Spain.
  • Turri S; Novartis Pharma S.A.S, Rueil-Malmaison, France.
  • Maier J; Novartis Pharma AG, Basel, Switzerland.
  • Csonka D; Novartis Pharma AG, Basel, Switzerland.
  • Chakravartty A; Novartis Healthcare Pvt. Ltd., Hyderabad, India.
  • Fizazi K; Department of Cancer Medicine, Gustave Roussy, University of Paris Sud, France.
Eur J Cancer ; 81: 242, 2017 08.
Article em En | MEDLINE | ID: mdl-28606464

Texto completo: 1 Base de dados: MEDLINE Idioma: En Ano de publicação: 2017 Tipo de documento: Article

Texto completo: 1 Base de dados: MEDLINE Idioma: En Ano de publicação: 2017 Tipo de documento: Article